Jan A Graw1, Claire Mayeur1, Ivy Rosales1, Yumin Liu1, Venkata S Sabbisetti1, Frank E Riley1, Osher Rechester1, Rajeev Malhotra1, H Shaw Warren1, Robert B Colvin1, Joseph V Bonventre1, Donald B Bloch1, Warren M Zapol2. 1. From Anesthesia Center for Critical Care Research of the Department of Anesthesia, Critical Care, and Pain Medicine (J.A.G., C.M., D.B.B., W.M.Z.), Department of Pathology (I.R., R.B.C.), Department of Pediatrics (F.E.R., O.R., H.S.W.), Cardiovascular Research Center and Cardiology Division, Department of Medicine (R.M.), and Division of Rheumatology, Allergy and Immunology, Department of Medicine (D.B.B.), Massachusetts General Hospital, Harvard Medical School, Boston; and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (Y.L., V.S.S., H.S.W.). 2. From Anesthesia Center for Critical Care Research of the Department of Anesthesia, Critical Care, and Pain Medicine (J.A.G., C.M., D.B.B., W.M.Z.), Department of Pathology (I.R., R.B.C.), Department of Pediatrics (F.E.R., O.R., H.S.W.), Cardiovascular Research Center and Cardiology Division, Department of Medicine (R.M.), and Division of Rheumatology, Allergy and Immunology, Department of Medicine (D.B.B.), Massachusetts General Hospital, Harvard Medical School, Boston; and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (Y.L., V.S.S., H.S.W.). wzapol@mgh.harvard.edu.
Abstract
BACKGROUND: Extracellular hemoglobin and cell-free heme are toxic breakdown products of hemolyzed erythrocytes. Mammals synthesize the scavenger proteins haptoglobin and hemopexin, which bind extracellular hemoglobin and heme, respectively. Transfusion of packed red blood cells is a lifesaving therapy for patients with hemorrhagic shock. Because erythrocytes undergo progressive deleterious morphological and biochemical changes during storage, transfusion of packed red blood cells that have been stored for prolonged intervals (SRBCs; stored for 35-40 days in humans or 14 days in mice) increases plasma levels of cell-free hemoglobin and heme. Therefore, in patients with hemorrhagic shock, perfusion-sensitive organs such as the kidneys are challenged not only by hypoperfusion but also by the high concentrations of plasma hemoglobin and heme that are associated with the transfusion of SRBCs. METHODS: To test whether treatment with exogenous human haptoglobin or hemopexin can ameliorate adverse effects of resuscitation with SRBCs after 2 hours of hemorrhagic shock, mice that received SRBCs were given a coinfusion of haptoglobin, hemopexin, or albumin. RESULTS: Treatment with haptoglobin or hemopexin but not albumin improved the survival rate and attenuated SRBC-induced inflammation. Treatment with haptoglobin retained free hemoglobin in the plasma and prevented SRBC-induced hemoglobinuria and kidney injury. In mice resuscitated with fresh packed red blood cells, treatment with haptoglobin, hemopexin, or albumin did not cause harmful effects. CONCLUSIONS: In mice, the adverse effects of transfusion with SRBCs after hemorrhagic shock are ameliorated by treatment with either haptoglobin or hemopexin. Haptoglobin infusion prevents kidney injury associated with high plasma hemoglobin concentrations after resuscitation with SRBCs. Treatment with the naturally occurring human plasma proteins haptoglobin or hemopexin may have beneficial effects in conditions of severe hemolysis after prolonged hypotension.
BACKGROUND: Extracellular hemoglobin and cell-free heme are toxic breakdown products of hemolyzed erythrocytes. Mammals synthesize the scavenger proteins haptoglobin and hemopexin, which bind extracellular hemoglobin and heme, respectively. Transfusion of packed red blood cells is a lifesaving therapy for patients with hemorrhagic shock. Because erythrocytes undergo progressive deleterious morphological and biochemical changes during storage, transfusion of packed red blood cells that have been stored for prolonged intervals (SRBCs; stored for 35-40 days in humans or 14 days in mice) increases plasma levels of cell-free hemoglobin and heme. Therefore, in patients with hemorrhagic shock, perfusion-sensitive organs such as the kidneys are challenged not only by hypoperfusion but also by the high concentrations of plasma hemoglobin and heme that are associated with the transfusion of SRBCs. METHODS: To test whether treatment with exogenous humanhaptoglobin or hemopexin can ameliorate adverse effects of resuscitation with SRBCs after 2 hours of hemorrhagic shock, mice that received SRBCs were given a coinfusion of haptoglobin, hemopexin, or albumin. RESULTS: Treatment with haptoglobin or hemopexin but not albumin improved the survival rate and attenuated SRBC-induced inflammation. Treatment with haptoglobin retained free hemoglobin in the plasma and prevented SRBC-induced hemoglobinuria and kidney injury. In mice resuscitated with fresh packed red blood cells, treatment with haptoglobin, hemopexin, or albumin did not cause harmful effects. CONCLUSIONS: In mice, the adverse effects of transfusion with SRBCs after hemorrhagic shock are ameliorated by treatment with either haptoglobin or hemopexin. Haptoglobin infusion prevents kidney injury associated with high plasma hemoglobin concentrations after resuscitation with SRBCs. Treatment with the naturally occurring human plasma proteins haptoglobin or hemopexin may have beneficial effects in conditions of severe hemolysis after prolonged hypotension.
Authors: Chenell Donadee; Nicolaas J H Raat; Tamir Kanias; Jesús Tejero; Janet S Lee; Eric E Kelley; Xuejun Zhao; Chen Liu; Hannah Reynolds; Ivan Azarov; Sheila Frizzell; E Michael Meyer; Albert D Donnenberg; Lirong Qu; Darrel Triulzi; Daniel B Kim-Shapiro; Mark T Gladwin Journal: Circulation Date: 2011-07-11 Impact factor: 29.690
Authors: Marie E Steiner; Paul M Ness; Susan F Assmann; Darrell J Triulzi; Steven R Sloan; Meghan Delaney; Suzanne Granger; Elliott Bennett-Guerrero; Morris A Blajchman; Vincent Scavo; Jeffrey L Carson; Jerrold H Levy; Glenn Whitman; Pamela D'Andrea; Shelley Pulkrabek; Thomas L Ortel; Larissa Bornikova; Thomas Raife; Kathleen E Puca; Richard M Kaufman; Gregory A Nuttall; Pampee P Young; Samuel Youssef; Richard Engelman; Philip E Greilich; Ronald Miles; Cassandra D Josephson; Arthur Bracey; Rhonda Cooke; Jeffrey McCullough; Robert Hunsaker; Lynne Uhl; Janice G McFarland; Yara Park; Melissa M Cushing; Charles T Klodell; Ravindra Karanam; Pamela R Roberts; Cornelius Dyke; Eldad A Hod; Christopher P Stowell Journal: N Engl J Med Date: 2015-04-09 Impact factor: 91.245
Authors: József Balla; Gregory M Vercellotti; Viktória Jeney; Akihiro Yachie; Zsuzsa Varga; Harry S Jacob; John W Eaton; György Balla Journal: Antioxid Redox Signal Date: 2007-12 Impact factor: 8.401
Authors: Binglan Yu; Michael J Raher; Gian Paolo Volpato; Kenneth D Bloch; Fumito Ichinose; Warren M Zapol Journal: Circulation Date: 2008-04-07 Impact factor: 29.690
Authors: Santiago R Leal-Noval; Irene Jara-López; José L García-Garmendia; Ana Marín-Niebla; Angel Herruzo-Avilés; Pedro Camacho-Laraña; Jesús Loscertales Journal: Anesthesiology Date: 2003-04 Impact factor: 7.892
Authors: V Eric Kerchberger; Julie A Bastarache; Ciara M Shaver; Hiromasa Nagata; J Brennan McNeil; Stuart R Landstreet; Nathan D Putz; Wen-Kuang Yu; Jordan Jesse; Nancy E Wickersham; Tatiana N Sidorova; David R Janz; Chirag R Parikh; Edward D Siew; Lorraine B Ware Journal: JCI Insight Date: 2019-11-01
Authors: Nicolas S Merle; Anne Grunenwald; Helena Rajaratnam; Viviane Gnemmi; Marie Frimat; Marie-Lucile Figueres; Samantha Knockaert; Sanah Bouzekri; Dominique Charue; Remi Noe; Tania Robe-Rybkine; Marie Le-Hoang; Nathan Brinkman; Thomas Gentinetta; Monika Edler; Sara Petrillo; Emanuela Tolosano; Sylvia Miescher; Sylvain Le Jeune; Pascal Houillier; Sophie Chauvet; Marion Rabant; Jordan D Dimitrov; Veronique Fremeaux-Bacchi; Olivier P Blanc-Brude; Lubka T Roumenina Journal: JCI Insight Date: 2018-06-21
Authors: Michael Hugelshofer; Raphael M Buzzi; Christian A Schaer; Henning Richter; Kevin Akeret; Vania Anagnostakou; Leila Mahmoudi; Raphael Vaccani; Florence Vallelian; Jeremy W Deuel; Peter W Kronen; Zsolt Kulcsar; Luca Regli; Jin Hyen Baek; Ivan S Pires; Andre F Palmer; Matthias Dennler; Rok Humar; Paul W Buehler; Patrick R Kircher; Emanuela Keller; Dominik J Schaer Journal: J Clin Invest Date: 2019-12-02 Impact factor: 14.808
Authors: María García-Roa; María Del Carmen Vicente-Ayuso; Alejandro M Bobes; Alexandra C Pedraza; Ataúlfo González-Fernández; María Paz Martín; Isabel Sáez; Jerard Seghatchian; Laura Gutiérrez Journal: Blood Transfus Date: 2017-05 Impact factor: 3.443
Authors: Jill M Cholette; Anthony P Pietropaoli; Kelly F Henrichs; George M Alfieris; Karen S Powers; Francisco Gensini; Jeffrey S Rubenstein; Dawn Sweeney; Richard Phipps; Sherry L Spinelli; Majed A Refaai; Michael P Eaton; Neil Blumberg Journal: Transfusion Date: 2018-03-30 Impact factor: 3.157
Authors: Saurabh Aggarwal; Israr Ahmad; Adam Lam; Matthew A Carlisle; Changzhao Li; J Michael Wells; S Vamsee Raju; Mohammad Athar; Steven M Rowe; Mark T Dransfield; Sadis Matalon Journal: JCI Insight Date: 2018-11-02
Authors: Kenneth E Remy; Irene Cortés-Puch; Steven B Solomon; Junfeng Sun; Benjamin M Pockros; Jing Feng; Juan J Lertora; Roy R Hantgan; Xiaohua Liu; Andreas Perlegas; H Shaw Warren; Mark T Gladwin; Daniel B Kim-Shapiro; Harvey G Klein; Charles Natanson Journal: JCI Insight Date: 2018-09-20